MOJO Day Trading is quickly becoming a name on Wall Street for stellar stock picking and trading education. ProTrader Mike will show you exactly how to become a profitable stock trader even if you're an beginning trader. The blog contains valuable information for both day and swing trading styles. Main Website = www.mojodaytrading.com
Tuesday, July 31, 2012
Monday, July 30, 2012
Sunday, July 29, 2012
Friday, July 27, 2012
Wednesday, July 25, 2012
Tuesday, July 24, 2012
Loss - $205 today - Traded $OREX, $GNOM, $XRTX, $BAC, $VXX
Screenshot of my trade screen - shows holding small positions overnight.
Market was going 2 pennies forward and 4 pennies back - no momentum at all. Was down $500 came back to be down $205. Holding 1200 Shares $OREX at 5.68 - it's very oversold and should bounce back from these lows. Target back to $6.00
$XRTX - holding it as downside is limited from the baseline chart and a strong pop back up is possible. Can get out $11.00+ range - see how it opens tomorrow.
$AAPL - after hours trading down 31 points to 572 - see what happens to sector tomorrow.
Monday, July 23, 2012
$EGHT - huge size on offer - Great Sign!
When ever they sit with huge size on the offer they alwasy take it out - should close towards the 53 high of 5.23 - own at 5.07
Thursday, July 19, 2012
Top Medical Technology Stocks Most Favored By The World's Largest Fund Managers
Furthermore, the following are other notable medical tefchnology companies (ex-biotech) that are among the top holdings of mega funds in the group, relative to their market-cap (see Table):
Complete Genomics Inc. (GNOM), that is a life sciences company that is engaged in the development and commercialization of an innovative DNA sequencing platform that can provide customers with data that is ready to be used for genome-based research, in which mega funds together hold 1.74 million or 5.1% of the outstanding shares;
Wednesday, July 18, 2012
SVNT - NEWS POSTS - COULD BE HUGE
Source - http://tinyurl.com/775482w
Pegloticase (Krystexxa) Kidney Disease and Dialysis 30-Jan-12 11:01 pm I am very positive about Pegloticase, believe that it is going to be one of the major drugs in the market for cure of KIDNEY DISASE addition to chronic gout and also thinking that it will be a major solution for DIALYSIS., am buying as much as possible since it was $2.20.
Here is article
PHILADELPHIA -- November 14, 2011 -- In patients with refractory chronic gout and stage 3 and 4 chronic kidney disease (CKD), treatment with pegloticase for up to 6 months has no deleterious renal effects, researchers said here November 10 at the American Society of Nephrology (ASN) Kidney Week 2011.
Patients with chronic disabling gout refractory to conventional urate-lowering therapy need timely treatment to control disease manifestations related to tissue urate crystal deposition. Pegloticase was developed to fulfil this need.
“Pegloticase was developed for the treatment of chronic disabling gout that is refractory to conventional urate-lowering therapy,” said Marsha Wolfson, MD, Savient Pharmaceuticals, East Brunswick, New Jersey. “Our results showed that therapy with pegloticase for up to 6 months in patients with stages 3 and 4 chronic kidney disease is efficacious and has no adverse renal effects.”
For the study, researchers evaluated data from 2 duplicate phase 3 clinical trials comparing pegloticase with placebo.
They analysed data from 103 patients with stage 3 or 4 CKD (49% of the entire cohort). Patients were treated with pegloticase 8 mg every 2 weeks (n = 42), pegloticase 8 mg every 4 weeks (n = 41), or placebo (n = 20).
Using estimated glomerular filtration rate (eGFR), researchers assessed renal function at weeks 0, 7, 13, 19, and 25 post randomisation in these patients using the 4-variable modification of diet in renal disease (MDRD) formula. At week 0, mean eGFR in patients treated every 2 weeks and every 4 weeks was 40 mL/min/1.73 m2, compared with 43 mL/min/1.73 m2 in those treated with placebo. At week 25, eGFR was 42 mL/min/1.73 m2 in those treated every 2 weeks, and 41 mL/min/1.73 m2 in those treated every 4 weeks, compared with 47 mL/min/1.73 m2 in those treated with placebo at 47 mL/min/1.73 m2.
Changes in eGFR over time were not differentially affected by treatment (P =.28), and no discontinuation pattern was seen. The most common adverse events included gout flare and infusion reaction. Funding for this study was provided by Savient Pharmaceuticals Inc. [Presentation title: Effect of Pegloticase (PGL) on Renal Function in Patients With Chronic Kidney Disease (CKD).
$SVNT - they key!!! - Short Interest 50% of float - come on!!!!
Short % of Float (as of Jun 29, 2012)3: 48.80%
Shares Short (prior month)3: 29.42M
Tuesday, July 17, 2012
Subscribe to:
Posts (Atom)